Description: As IFRS 17 Insurance Contracts casts its net wide, reinsurers find themselves sailing toward new horizons of financial reporting. The transition to IFRS 17 is not just a regulatory compliance exercise but a transformational journey that reshapes the financial reporting landscape for reinsurers. The enhanced disclosure requirements, the granular contract-level accounting, and the measurement consistency across different reinsurance contracts promise to unveil a clearer financial picture. Yet, these new reporting waters could be choppy, demanding a sturdy understanding and application of IFRS 17's principles. This article describes benchmarking of IFRS 17 information provided at HY 2023 for four reinsurers.

Description: This article provides a description of three factor updates for the NAIC Risk-Based Capital that will take effect in 2012.

Description: An overview of John Robinson's experience at the recently concluded annual meeting of the Caribbean Actuarial Association in Trinidad.

Description: Gain a high-level understanding on how long-duration targeted improvement (LDTI) impacts insurance products and earnings. Explore highlights on secondary impacts to companies due to additional complexity of LDTI, such as a need for a source of earnings analysis. Then dive into the details and hear an explanation on how earnings emergence differs for each type of life and annuity product impacted by LDTI. Finally, discuss the impact -to-earnings volatility under LDTI for each product type. Close the session by connecting how the investor story changes with all the impacts discussed during the session.You should walk away with a good understanding of LDTI earnings emergence, which is a topic that has very limited thought leadership available today.

Description: Join a discussion on the tax implications for direct writers ceding annuity blocks for both onshore and offshore reinsurance arrangements. Get an introduction to the tax consequences of the risk transfer of annuity features and guarantees to reinsurers to reinsurers that are U.S.-based and not U.S. domiciled.

Description: In this session, presenters will share the impacts of transition to IFRS 17 on equity and various KPIs across insurance companies (Life & P&C), as well as share some observations of what the IFRS 17 landscape looks like across different global regions. The session will conclude with lessons learned and expectations for emerging practices under IFRS 17 globally.

Description: With large public filers having adopted LDTI in 2023, company practices are continuing to evolve as it relates to experience monitoring, assumption unlocking, as well as both internal and external communication and disclosures related to assumptions. In this diverse session featuring representatives from both insurance companies as well as industry analysts, we'll explore how companies approach emerging experience in a given year through a case study approach. The moderator will explore various topics such as off-cycle experience monitoring, experience outliers, simplifications and approximations, and materiality considerations. Each 'what-if' scenario will start with a prompt from the moderator, discussion among the industry panelists as to how they would approach the situation within their own organization, followed by commentary from the analysts as to how they might expect companies to respond in each case. Audience participation will be encouraged to explore potential alternative approaches in an engaging, interactive session.

Description: The document is a Request for Proposals (RFP) for a research study on offshore life and annuity jurisdictions' reinsurance landscapes, commissioned by the Society of Actuaries Reinsurance Section. It outlines the background, purpose, research objectives, proposal requirements, selection process, submission details, and other related information.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: Have you wondered: - As a U.S. insurer, should I try to understand the implication of International Financial Reporting Standard 17 (IFRS 17) on global insurers? - As a pricing actuary, do I need to learn about the financial evolution brought about by IFRS 17 and Long Duration Targeted Improvements (LDTI)? - As my organization's CFO, I have invested in the arduous implementation of the new standards. How do I get the best return on my investment?If the answer to any of the above is 'Yes,' then this session is for you!